Prepaid and other current assets consisted of the following as of March 31, 2024 and December 31, 2023 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2024 |
|
|
2023 |
|
Down payments for inventory |
|
|
13,828 |
|
|
|
16,296 |
|
Prepaid research and development |
|
|
12,626 |
|
|
|
13,931 |
|
Other prepaid expenses |
|
|
16,709 |
|
|
|
8,593 |
|
Total prepaid expenses |
|
$ |
43,163 |
|
|
$ |
38,820 |
|
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2024 |
|
|
2023 |
|
Royalties receivable |
|
$ |
4,499 |
|
|
$ |
3,054 |
|
Receivable from collaboration agreement(1) |
|
|
— |
|
|
|
15,000 |
|
Deposits and other current assets |
|
|
7,620 |
|
|
|
4,354 |
|
Total other current assets |
|
$ |
12,119 |
|
|
$ |
22,408 |
|
(1) In January 2024 the Company waived the remaining reimbursement payment of $15.0 million from Sobi in connection with the decision to discontinue the cold agglutinin disease (CAD) program.
|